From brain to blood: New biomarkers for ischemic stroke prognosis

Journal of Proteomics

Volumn 94, Issue , 2013, Pages 138-148

  García Berrocoso, Teresa ^a   Penalba, Anna ^a   Boada, Cristina ^a   Giralt, Dolors ^a   Cuadrado, Eloy ^a,c   Colomé, Núria ^a   Dayon, Loïc ^b,d   Canals, Francesc ^a   Sanchez, Jean Charles ^b   Rosell, Anna ^a   Montaner, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Biomarker; Brain; Mortality; Orbitrap; Prognosis; Stroke

Indexed keywords

ALCOHOL DEHYDROGENASE; ALPHA AMINOADIPIC SEMIALDEHYDE DEHYDROGENASE; AMINOTRANSFERASE; BIOLOGICAL MARKER; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GELSOLIN; GLUTATHIONE TRANSFERASE M2; LACTATE DEHYDROGENASE; OXIDOREDUCTASE; PHOSPHOSERINE AMINOTRANSFERASE; STEFIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN HOMOGENATE; BRAIN ISCHEMIA; BRAIN TISSUE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; STROKE PATIENT;

BIOMARKER; BRAIN; MORTALITY; ORBITRAP; PROGNOSIS; STROKE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; STROKE;

EID: 84885207281     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.09.005     Document Type: Article

References (50)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
2. Strbian D., Meretoja A., Ahlhelm F.J., Pitkäniemi J., Lyrer P., Kaste M., et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology 2012, 78:427-432.
3. Ntaios G., Faouzi M., Ferrari J., Lang W., Vemmos K., Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology 2012, 78:1916-1922.
4. O'Donnell M.J., Fang J., D'Uva C., Saposnik G., Gould L., McGrath E., et al. Investigators of the Registry of the Canadian Stroke Network. The PLAN score: a bedside prediction rule for death and severe disability following acute ischemic stroke. Arch Intern Med 2012, 172:1548-1556.
5. Saposnik G., Kapral M.K., Liu Y., Hall R., O'Donnell M., Raptis S., et al. Investigators of the Registry of the Canadian Stroke Network, Stroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation 2011, 123:739-749.
6. Whiteley W., Chong W.L., Sengupta A., Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009, 40:e380-e389.
7. De Marchis G.M., Katan M., Weck A., Fluri F., Foerch C., Findling O., et al. Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 2013, 80:1278-1286.
8. Cuadrado E., Rosell A., Colomé N., Hernández-Guillamon M., García-Berrocoso T., Ribó M., et al. The proteome of human brain after ischemic stroke. J Neuropathol Exp Neurol 2010, 69:1105-1115.
9. Mendioroz M., Fernández-Cadenas I., Rosell A., Delgado P., Domingues-Montanari S., Ribó M., et al. Osteopontin predicts long-term functional outcome among ischemic stroke patients. J Neurol 2011, 258:486-493.
10. Brott T., Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000, 343:710-722.
11. Scherl A., Tsai Y.S., Shaffer S.A., Goodlett D.R. Increasing information from shotgun proteomic data by accounting for misassigned precursor ion masses. Proteomics 2008, 8:2791-2797.
12. König I.R., Ziegler A., Bluhmki E., Hacke W., Bath P.M.W., Sacco R.L., et al. Weimar C, on behalf of the Virtual International Stroke Trials Archive (VISTA) Investigators. Stroke 2008, 39:1821-1826.
13. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
14. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
15. Pickering J.W., Endre Z.H. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol 2012, 7:1355-1364.
16. Whiteley W., Wardlaw J., Dennis M., Lowe G., Rumley A., Sattar N., et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012, 43:86-91.
17. Scigelova M., Makarov A. Advances in bioanalytical LC-MS using the Orbitrap™ mass analyzer. Bioanalysis 2009, 1:741-754.
18. Grumet M. Nr-CAM: a cell adhesion molecule with ligand and receptor functions. Cell Tissue Res 1997, 290:423-428.
19. Mikami T., Yasunaga D., Kitagawa H. Contactin-1 is a functional receptor for neuroregulatory chondroitin sulfate-E. J Biol Chem 2009, 284:4494-4499.
20. Tabatabaie L., Klomp L.W., Berger R., de Koning T.J. L-Serine síntesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab 2010, 99:256-262.
21. Schneider G., Nieznanski K., Jozwiak J., Slomnicki L.P., Redowicz M.J., Filipek A. Tubulin binding protein, CacyBP/SIP, induces actin polymerization and may link actin and tubulin cytoskeletons. Biochim Biophys Acta 1803, 2010:1308-1317.
22. Schneider G., Filipek A. S100A6 binding protein and Siah-1 interacting protein (CacyBP/SIP): spotlight on properties and cellular function. Amino Acids 2011, 41:773-780.
23. Davalos D., Ryu J.K., Merlini M., Baeten K.M., Le Moan N., Petersen M.A., et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun Nat Commun 2012, 3:1227.
24. Jood K., Danielson J., Ladenvall C., Blomstrand C., Jern C. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost 2008, 6:897-904.
25. del Zoppo G.J., Levy D.E., Wasiewski W.W., Pancioli A.M., Demchuk A.M., Trammel J., et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009, 40:1687-1691.
26. Cho H., Shimazaki K., Takeuchi K., Kobayashi S., Watanabe K., Oguro K., et al. Biphasic changes in F3/contactin expression in the gerbil hippocampus after transient ischemia. Exp Brain Res 1998, 122:227-234.
27. Silacci P., Mazzolai L., Gauci C., Stergiopulos N., Yin H.L., Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004, 61:2614-2623.
28. Endres M., Fink K., Zhu J., Stagliano N.E., Bondada V., Geddes J.W., et al. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest 1999, 103:347-354.
29. Park S.M., Hwang I.K., Kim S.Y., Lee S.J., Park K.S., Lee S.T. Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics 2006, 6:1192-1199.
30. Haverland N., Pottiez G., Wiederin J., Ciborowski P. Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation. J Transl Med 2010, 8:137.
31. Bucki R., Levental I., Kulakowska A., Janmey P.A. Plasma gelsolin: function, prognostic value and potential therapeutic use. Curr Protein Pept Sci 2008, 9:541-551.
32. Pottiez G., Haverland N., Ciborowski P. Mass spectrometric characterization of gelsolin isoforms. Rapid Commun Mass Spectrom 2010, 24:2620-2624.
33. Chou S.H.Y., Lee P.S., Konigsberg R.G., Gallacci D., Chiou T., Arai K., et al. Plasma type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke 2011, 42:3624-3627.
34. Xu J.F., Liu W.G., Dong X.Q., Yang S.B., Fan J. Change in plasma gelsolin level after traumatic brain injury. J Trauma 2010, 72:491-496.
35. Zhao D.Q., Wang K., Zhang H.D., Li Y.J. Significant reduction of plasma gelsolin levels in patients with intracerebral hemorrhage. Clin Chim Acta 2013, 415:202-206.
36. Guo X.C., Luo B.Y., Li X.F., Yang D.G., Zheng X.N., Zhang K. Plasma gelsolin levels and 1-year mortality after first-ever ischemic stroke. J Crit Care 2011, 26:608-612.
37. Arimura N., Menager C., Fukata Y., Kaibuchi K. Role of CRMP-2 in neuronal polarity. J Neurobiol 2004, 58:34-47.
38. Hensley K., Venkova K., Christov A., Gunning W., Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 2011, 43:180-191.
39. Chung M.A., Lee J.E., Lee J.Y., Ko M.J., Lee S.T., Kim H.J. Alteration of collapsin response mediator protein-2 expression in focal ischemic rat brain. Neuroreport 2005, 16:1647-1653.
40. Chen A., Liao W.P., Lu Q., Wong W.S.F., Wong P.T.H. Upregulation of dihydropyrimidinase-related protein 2, spectrin α II chain, heat shock cognate protein 70 pseudogene 1 and tropomodulin 2 after focal cerebral ischemia in rats - a proteomics approach. Neurochem Int 2007, 50:1078-1086.
41. Maurer M.H., Berger C., Wolf M., Fütterer C.D., Feldmann R.E., Schwab S., et al. The proteome of human brain microdialysate. Proteome Sci 2003, 1:7.
42. Dayon L., Turck N., García-Berrocoso T., Walter N., Burkhard P.R., Vilalta A., et al. Brain extracellular fluid protein changes in acute stroke patients. J Proteome Res 2011, 10:1043-1051.
43. da Silva J.S., Dotti C.G. Breaking the neuronal sphere: regulation of the actin cytoskeleton in neuritogenesis. Nat Rev Neurosci 2002, 3:694-704.
44. Ray S., Lukyanov P., Ochieng J. Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities. Biochim Biophys Acta 2003, 1652:91-102.
45. Brzin J., Kopitar M., Turk V. Protein inhibitors of cysteine proteinases. I. Isolation and characterization of stefin, a cytosolic protein inhibitor of cysteine proteinases from human polymorphonuclear granulocytes. Hoppe Seylers Z Physiol Chem 1983, 364:1475-1480.
46. Buttle D.J., Burnett D., Abrahamson M. Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: relationship to inflammation. Scand J Clin Lab Invest 1990, 50:509-516.
47. Cuadrado E., Ortega L., Hernández-Guillamon M., Penalba A., Fernández-Cadenas I., Rosell A., et al. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 2008, 84:207-214.
48. Seyfried D., Han Y., Zheng Z., Day N., Moin K., Rempel S., et al. Cathepsin B and middle cerebral artery occlusion in the rat. J Neurosurg 1997, 87:716-723.
49. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
50. Whiteley W., Jackson C., Lewis S., Lowe G., Rumley A., Sandercock P., et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009, 6:e1000145.